We aimed to evaluate the relationship between on-ticagrelor PR, assessed by the vasodilator-stimulated phosphoprotein index (VASP), and thrombotic and bleeding events in patients with acute coronary syndrome (ACS) treated by percutaneous coronary intervention (PCI).
In this study, phosphorylation levels of vasodilator stimulated phosphoprotein (VASP) were detected by flow cytometry (FCM) to investigate the effects of ticagrelor and clopidogrel on platelet aggregation function (PAF) after percutaneous coronary intervention (PCI) in patients with acute coronary syndrome (ACS).
This study sought to compare long-term outcomes between clopidogrel responders (platelet reactivity index [PRI] vasodilator-stimulated phosphoprotein [VASP] <61%) and patients under prasugrel or ticagrelor therapy following PCI-treated ACS.
Platelet reactivity was evaluated after ACS (>30 days) by measuring residual platelet aggregation (RPA) to aspirin and to P2Y12 inhibitors with light transmission aggregometry (LTA), VerifyNow aspirin assay (ARU), and P2Y12 assay (PRU) and with the VASP platelet reactivity index (VASP-PRI).